13 C-breath tests are widely applied as a tool to investigate metabolic processes and infectious diseases, but most of them have not yet entered into clinical practice. In order to promote the introduction of more 13 C-breath tests into clinical routine application we evaluated the tests so far known with respect to some reasonable criteria, which are valued by one of three marks. The sum ∑ of these marks is assumed as a measure of the total value of the respective 13 C-breath test. In this way we arrived at 10 tests with a ∑ value of 10 or more points which seem to have an especially high potential to successfully enter into clinical practice. This is particularly true for the 13 Cbreath tests with urea, aminopyrine, acetate, galactose, caffeine, octanoic acid, and phenylalanine as substrates. Measures are proposed for promoting the clinical application of such tests.
Introduction
Breath tests have proven to be good tools to investigate metabolic processes. Usually such tests are carried out as follows [1] [2] [3] . The person to be studied takes in a certain amount of a carbon compound or a product containing carbon labeled with its stable isotope 13 C. If this carbon is transformed into carbon dioxide and if this transformation is the rate-determining step of the metabolic degradation of the substance taken in, we can characterize the kinetics of this metabolic process by measuring the 13 C-content of the exhaled carbon dioxide in dependence on time. Radioactive labeling of carbon using 14 C can be easily followed by scintillation counting, but it cannot be used for children and pregnant women and it is scorned for use in others because of its radiation risks. On the other hand labeling with the stable isotope 13 C does not imply any radiation risk. The isotope analysis can be performed either mass-spectrometrically or by optical spectrometry. In the form of nondispersive infrared spectrometry the latter method becomes increasingly important, because it implies simple devices which can easily be operated. Figure 1 demonstrates one of the two nondispersive infrared spectrometric devices we have developed and now produce for carrying out 13 C-breath tests. The compact device is particularly attractive for medical and laboratory practices and small hospitals. The white box on the right hand side contains the optical system with its cuvettes, infrared sources and infrared detectors, and the gas management system. The bags with the breath samples are attached to one of four connecting pieces in front of the box. The computer on the left side is connected to the analyzer. 13 C-breath tests are good tools to use to investigate metabolic processes and for diagnosing metabolic and infectious diseases (table 1). The left column specifies the types of substrates used for 13 C-breath tests and the right one the metabolic implications, which can be achieved by such tests.
Monosaccharides labeled with 13 C can be used to investigate absorption and utilization of monosaccharides and hepatic microsomal biotransformation. Some oligo-and polysaccharides are used for exploring their hydrolysis and for studying pancreatic function and cystic fibrosis. Certain amino acids labeled with 13 C are valid for investigating their catabolism, for controlling phenylketonuria diet-therapy, for measuring gastric emptying, and for studying hepatic function. Digestion and absorption of proteins is explored using 13 Clabeled proteins. Certain carboxylic acids labeled with 13 C are can be used to measure gastric emptying and to study myocardial metabolic processes and hepatic stea-Heinz Fischer and Klaus Wetzel tosis. Fat metabolism, especially fat malabsorption, is investigated using 13 C-labeled lipids. Special derivatives of carbonic acid are used to determine gastrointestinal, intestinal, or orocoecal transit times.
The 13 C-urea breath test is not used to study the metabolism of the patients themselves, but to detect a special metabolic activity of a pathogenic microorganism in the patient. The bacterium Helicobacter pylori settling in the stomachs and duodena of more than 50% of all human beings excretes the enzyme urease, which cleaves urea to form carbon dioxide. A Helicobacter pylori infection therefore reveals itself by an unusually high 13 C content in breath 20 or 30 minutes after oral urea intake. The test, which is considered to be the gold standard for diagnosing this infection, can be performed as shown in figure 2. It is particularly valuable for monitoring Helicobacter pylori infection therapy and for epidemiological investigations about this infection.
Braden et al. [4] tested the diagnostic capability of the 13 C-urea breath test using both mass spectrometry and our nondispersive infrared spectrometer FANci2 for isotope analysis on a group of 142 patients with dyspeptic symptoms. The mean difference between the two methods was as small as 0.28 δ-units. In spite of their widespread application in a qualitative as well as in a quantitative sense, most of the approximately 50 13 C-breath tests known are not yet used in clinical routine application.
No wonder that the procedures are preferentially directed to high cognitive yield rather than to easy and reasonable implementation, e.g., with respect to amount and price of the substrate, the duration of the test or the number of breath samples. 
Method
In order to promote the introduction of more 13 C-breath tests into clinical routine application we evaluated the tests so far known with respect to the following criteria [5] : abundance and significance of the metabolic disorder or infection to be investigated, want of attractive alternatives, sensitivity and specificity, speed, price of substrate to be applied, number of breath samples to be collected and analyzed, and topicality. Each of these seven points of view is valued as either 2 = favorable, 1 = satisfactory, or 0 = unfavorable. The sum ∑ of these values, i.e., up to 7 × 2 = 14, is assumed as a measure of the total value of the respective 13 C-breath test.
Results
As table 2 shows, we arrived at 10 of approximately 50 tests with a total sum of ten or more points, which seem to have an especially high potential to successfully enter into clinical practice. The 13 C-urea breath test is already validated for clinical application by the appropriate governmental authorities in many countries.
A few other 13 C-breath tests are already validated in some countries. Following these results we concluded that the 13 Cbreath tests with the substrates presented in table 3 probably have the greatest chance to attain worldwide clinical routine application: ∑ = 13: urea, aminopyrine, galactose; ∑ = 12: acetate; ∑ = 11: caffeine, octanoate, phenylalanine; ∑ = 10: trioctanoine, glucose, lactose.
Conclusions
From the investigations summarized in table 3. We infer that the efforts towards introduction into clinical practice for 13 C-breath tests, such as the 13 C-urea breath test, the 13 C-acetate breath test, and the 13 C-octanoic Many other substrates for 13 C-breath tests will be found which make use of such a fascinating and simple way to obtain and measure samples for characterizing metabolic processes in humans. Foods, their constituents, like amino acids, carbohydrates, fatty acids, or triglycerides as well as xenobiotics, especially pharmaceuticals, will be used as substrates of 13 C-breath tests. 
